מדינה: ישראל
שפה: אנגלית
מקור: Ministry of Health
RIVAROXABAN
TARO PHARMACEUTICAL INDUSTRIES LTD
B01AX06
FILM COATED TABLETS
RIVAROXABAN 20 MG
PER OS
Required
TARO PHARMACEUTICAL INDUSTRIES LTD
RIVAROXABAN
* Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.* Treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
2019-08-06
SAFETY INFORMATION CARD FOR PATIENTS UNDER ANTICOAGULANT TREATMENT WITH RIVAROXABAN TARO RIVAROXABAN TARO 2.5 MG RIVAROXABAN TARO 10 MG RIVAROXABAN TARO 15 MG RIVAROXABAN TARO 20 MG Keep this card with you at all times Present this card to every doctor or dentist at the beginning of the visit THE PATIENT CARRYING THIS CARD IS UNDER ANTICOAGULANT TREATMENT WITH RIVAROXABAN TARO Name _________________________________________________ Address _______________________________________________ Date of birth ___________________ Weight ___________________ Information regarding concomitant diseases and medications _____________________________ INFORMATION IN CASE OF EMERGENCY IN CASE OF EMERGENCY, PLEASE INFORM THE TREATING DOCTOR ______________________ Telephone ______________________________________________ PLEASE ALSO NOTIFY: Name _____________________Relationship ______________ Telephone ______________________________________________ Emergency phone (clinic/first aid) _________________________ INFORMATION REGARDING USE OF THE MEDICINE Treatment start date __________________________________ Indication ___________________________________________ Dosage and administration regimen ______________________ Renal function at treatment onset (creatinine clearance mL/min) ___________________________________________________ INFORMATION FOR HEALTHCARE PROVIDERS: Measuring INR is not suitable for assessment of the anticoagulant activity of Rivaroxaban Taro and should therefore not be used for this purpose. INFORMATION ON ANTICOAGULANTS AND GUIDANCE FOR THE PATIENT The anticoagulant, Rivaroxaban Taro, is a blood thinner, which protects you from the development of dangerous blood clots. Rivaroxaban Taro must be taken exactly as prescribed by your doctor. To ensure optimal protection from blood clots, you should strictly comply with the administration schedule as recommended by your doctor and do not skip any dose, unless instructed by your doctor. Do not stop taking Rivaroxaban Taro without consulting your doctor, as your קרא את המסמך השלם